Arrowhead Pharmaceuticals, Inc.

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals is dedicated to developing innovative therapies using RNAi (RNA interference) technology to target and silence genes that cause diseases. Their mission focuses on addressing significant unmet medical needs with a fast-paced, unique approach through their proprietary TRiM™ platform. The company aims to have 20 products in clinical trials or on the market by 2025.

Products & Services

Plozasiran (ARO-APOC3):A therapy designed to reduce Apolipoprotein-CIII (ApoC3) production via RNAi, targeting severe hypertriglyceridemia to lower triglycerides and normalize lipid levels. Currently in Phase 3 clinical trials.

Zodasiran (ARO-ANG3):A treatment aimed at reducing angiopoietin-like protein 3 (ANGPTL3) to lower LDL and triglycerides, targeting dyslipidemia. Currently in Phase 2 clinical trials.

ARO-RAGE:A drug designed to reduce Receptor for Advanced Glycation End products (RAGE) for treating inflammatory pulmonary diseases. Currently in Phase 1/2a clinical trials.

Specialties

RNAi Technology Gene Silencing Cardiometabolic Diseases Pulmonary Diseases Severe Hypertriglyceridemia Dyslipidemia Inflammatory Pulmonary Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 625000000 MR: - FA: $625,000,000 FAN: 625000000	D: 2026-01-08 FD: 2026-01-08	5 investors
2	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 500000000 MR: - FA: $500 million FAN: 500000000	D: 2026-01-06 FD: 2026-01-06	2 investors
3	RT: Debt T: - FT: Debt	A: 500000000 MR: - FA: 500 million FAN: 500000000	D: 2024-08-08 FD: 2024-08-08	1 investors
4	RT: Milestone Payment T: - FT: Milestone Payment	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-05-02 FD: 2024-05-02	1 investors
5	RT: Underwritten Registered Offering T: - FT: Underwritten Registered Offering	A: 450000000 MR: - FA: 450.0 million FAN: 450000000	D: 2024-01-05 FD: 2024-01-05	5 investors
6	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 450000000 MR: - FA: $450.0 million FAN: 450000000	D: 2024-01-03 FD: 2024-01-03	3 investors

Convertible Senior Notes Latest

2026-01-08

$625.0M

5 investors (Pro only)

Convertible Senior Notes 2026-01-06

$500.0M

Debt 2024-08-08

$500.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Christopher Anzalone

President, CEO and Chairman of the Board

J

James Hamilton

Chief Medical Officer, Head of R&D

P

Patrick O'Brien, PharmD, JD

Chief Operating Officer and General Counsel

A

Andy Davis

Senior Vice President, Cardiovascular/Metabolic Franchise Head

D

Daniel Apel

Chief Financial Officer

M

Mauro Ferrari

President, CEO, and Board Chair of BrYet US, Inc.

View 9 more team members with Pro

Unlock Full Team Directory

Recent News